The FDA issued a conditional approval for Strattera on Aug. 14 but said that some new clinical studies might be needed to get the drug on the market.

FORBES: Magazine Article

More than 50% of the value of Savient shares has been added since June 12, when scientists at the FDA issued early findings that seemed to favor approval for Krystexxa, and June 16, when a panel of outside scientists picked by the FDA voted that Krystexxa should be approved.

FORBES: Drugs